Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel plus sunitinib vs docetaxel in first-line treatment of advanced breast cancer
2006-004693-27Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Oct 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in breast cancer comparing Docetaxel + sunitinib with Docetaxel alone (2 arms). Primary endpoint: Progression-free survival. Started Oct 2006; status: terminated.
02
Drugs
sunitinibdocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-004693-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004693-27.